Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

BTK inhibitor With vs Without a CD20-Targeted Antibody

July 30th 2020

Second-Generation BTK Inhibitors in CLL

July 30th 2020

Therapies in the Pipeline for Frontline CLL

July 30th 2020

Telemedicine for Patients With CLL

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

FDA Approval Sought for Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

July 29th 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Dr. Raje on the Effectiveness of Quadruplet Therapies in Multiple Myeloma

July 29th 2020

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Dr. Palmer on the Incidence of Graft-Versus-Host Disease

July 28th 2020

Jeanne M. Palmer, MD, discusses the prognosis and challenges of predicting graft-versus-host disease in patients who have undergone transplant.

Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases

July 27th 2020

An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib is effective at reducing lung inflammation in patients with severe novel coronavirus 2019, thereby decreasing incidences of mechanical ventilation and death in these patients.

ASCO and ACCC Collaborate to Boost Racial/Ethnic Representation in Cancer Treatment Trials

July 27th 2020

A new collaboration between the American Society of Clinical Oncology and the Association of Community Cancer Centers aims to encourage the enrollment of more racially and ethnically diverse patients with cancer onto clinical trials.

EU Panel Recommends Ibrutinib/Rituximab Combo for Frontline CLL

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.